Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial.

IF 8.2 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2025-07-03 DOI:10.3324/haematol.2025.288057

Alexey V Danilov,Hongli Li,Mazyar Shadman,Lisa Rimsza,Ahmad Zebari,Sonali M Smith,Michael LeBlanc,Jonathan W Friedberg,Christopher Carlson,Joo Y Song

引用次数: 0

Abstract

Not available.

查看原文本刊更多论文

在SWOG S0016试验中，最小残留疾病状态预测化疗免疫治疗的滤泡性淋巴瘤患者的预后。

不可用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.